← Back to patent-cliff list
Tilidine Hydrochloride/Naloxone
Tier C — Watch / tradeTilidine Hydrochloride/Naloxone
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Opioid receptors, MOR1
Indications (approved)：Cancer pain, Arthralgia, 急性疼痛, Chronic pain, 神经痛, Postoperative pain, Pain, 肠绞痛
Regional status
US
-
EU
-
China
Phase II
2014-04-03
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tilidine Hydrochloride/Naloxone?
Approved indications include: Cancer pain, Arthralgia, 急性疼痛, Chronic pain, 神经痛, Postoperative pain, Pain, 肠绞痛.
When does the Tilidine Hydrochloride/Naloxone patent expire?
No public expiry year is available for Tilidine Hydrochloride/Naloxone yet; this page updates once verified.
How do I get a quote for Tilidine Hydrochloride/Naloxone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12